CMOPF Stock Chart & Stats
$70.96
$1.63(2.18%)
At close: 4:00 PM EDT
$70.96
$1.63(2.18%)
Day’s Range― - ―
52-Week Range$59.02 - $169.90
Previous CloseN/A
Volume20.00
Average Volume (3M)464.00
Market Cap
$1.09B
Enterprise Value$963.95M
Total Cash (Recent Filing)$195.28M
Total Debt (Recent Filing)$4.33M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Mar 24, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.85%
Share Statistics
EPS (TTM)-0.38
Shares Outstanding17,543,522
10 Day Avg. Volume250
30 Day Avg. Volume464
Financial Highlights & Ratios
PEG Ratio4.78
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market Cap0.89
Enterprise Value/Revenue9.39
Enterprise Value/Gross Profit20.62
Enterprise Value/Ebitda-1.51K
Forecast
1Y Price Target
$139.38Price Target Upside96.42% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.17
Revenue Forecast (FY)$130.07M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity provide financial resilience while the company manages operating volatility. This supports continued investment in gastroenterology products and technologies, preserves flexibility for partnerships or development spending, and reduces exposure to refinancing pressure.
Diversified Revenue ModelCombining product sales with partnership and licensing income gives COSMO multiple ways to monetize its gastroenterology and endoscopy capabilities. This model can broaden geographic reach, share commercialization responsibilities, and create recurring royalty opportunities alongside direct product revenue.
Demonstrated Profit And Cash GenerationThe exceptionally strong 2024 results demonstrate that COSMO can produce substantial earnings and internally generated cash when commercial performance is favorable. That earning capacity can fund development, support partnerships, and strengthen the company’s strategic flexibility over multiple quarters.
Bears Say
Sharp Revenue ContractionThe steep year-over-year revenue decline indicates that the latest commercial run rate is materially weaker than the prior year. If sustained, lower sales would reduce operating leverage, constrain reinvestment capacity, and make future earnings more dependent on individual products or partnership outcomes.
Negative ProfitabilityOperating and bottom-line losses show that current revenue is not covering the company’s cost base, weakening the durability of earnings. Persistent negative margins could limit funding for product development and commercialization while increasing reliance on a future recovery in sales or partner economics.
Cash Flow DeteriorationThe shift from strong cash generation to operating and free cash outflows raises questions about the quality and sustainability of the current business performance. Continued cash burn would reduce the benefits of the conservative balance sheet and could restrict investment or shareholder-return capacity over time.
COSMO Pharmaceuticals N.V. News
CMOPF FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was $59.02 and its highest was $169.90 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is $1.09B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 24, 2027 which is in 149 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2026. The company reported -$0.325 earnings per share for the quarter, missing the consensus estimate of $0 by -$0.325.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of $2.463 which represents an annual dividend yield of 3.85%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -$0.325 in its last earnings report, missing expectations of $0. Following the earnings report the stock price went up 8.165%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CMOPF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo NV engages in the development and manufacture of treatments and products for gastrointestinal diseases and dermatology. Its products include Lialda/Mezavant/Mesavancol, Uceris/Cortiment, Winlevi, GI Genius, Lumeblue, Aemcolo/Relafalk, Eleview, and Byfavo. The company was founded by Mauro Severino Ajani in 1997 and is headquartered in Dublin, Ireland.
CMOPF Stock 12 Month Forecast
Average Price Target
$139.38
▲(96.42% Upside)
Technical Analysis
Ownership Overview
―
Insiders
7.76% Mutual Funds
0.05% Other Institutional Investors
88.78% Public Companies and
Individual Investors